Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling

Biochemical and Biophysical Research Communications

Volumn 423, Issue 4, 2012, Pages 684-689

  Li, Guofeng ^a   Xu, Jingren ^a   Li, Zengchun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell proliferation; ERK; PI3K; RAGE; Wnt

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLIN D1; DICKKOPF 1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; SECRETED FRIZZLED RELATED PROTEIN 1; WNT PROTEIN;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; IN VITRO STUDY; NONHUMAN; ONCOGENE C MYC; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; CELL LINE; CELL PROLIFERATION; GLYCOSYLATION END PRODUCTS, ADVANCED; MAP KINASE SIGNALING SYSTEM; MICE; OSTEOBLASTS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84863843679     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.015     Document Type: Article

References (28)

1. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
2. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2002, 2:389-406.
3. Glass D.A., Karsenty G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr. Top Dev. Biol. 2006, 73:43-84.
4. Baron R., Rawadi G. Wnt signaling and the regulation of bone mass. Curr. Osteoporos. Rep. 2007, 5:73-80.
5. Nusse R., Fuerer C., Ching W., Harnish K., Logan C., Zeng A., ten Berge D., Kalani Y. Wnt signaling and stem cell control. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:59-66.
6. Nusse R., Brown A., Papkoff J., Scambler P., Shackleford G., McMahon A., Moon R., Varmus H. A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 1991, 64:231.
7. Nusse R. Wnts and hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development (Cambridge, England) 2003, 130(2003):5297-5305.
8. Rowe P.S., de Zoysa P.A., Dong R., Wang H.R., White K.E., Econs M.J., Oudet C.L. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000, 67:54-68.
9. Fukumoto S., Hsieh C.M., Maemura K., Layne M.D., Yet S.F., Lee K.H., Matsui T., Rosenzweig A., Taylor W.G., Rubin J.S., Perrella M.A., Lee M.E. Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 2001, 276(2001):17479-17483.
10. Yun M.S., Kim S.E., Jeon S.H., Lee J.S., Choi K.Y. Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J. Cell. Sci. 2005, 118:313-322.
11. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J. Clin. Investig. 2006, 116(2006):1202-1209.
12. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M., Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G., Apte S., Adkins W.N., Allgrove J., Arslan-Kirchner M., Batch J.A., Beighton P., Black G.C., Boles R.G., Boon L.M., Borrone C., Brunner H.G., Carle G.F., Dallapiccola B., De Paepe A., Floege B., Halfhide M.L., Hall B., Hennekam R.C., Hirose T., Jans A., Jüppner H., Kim C.A., Keppler-Noreuil K., Kohlschuetter A., LaCombe D., Lambert M., Lemyre E., Letteboer T., Peltonen L., Ramesar R.S., Romanengo M., Somer H., Steichen-Gersdorf E., Steinmann B., Sullivan B., Superti-Furga A., Swoboda W., van den Boogaard M.J., Van Hul W., Vikkula M., Votruba M., Zabel B., Garcia T., Baron R., Olsen B.R., Warman M.L. Osteoporosis-pseudoglioma syndrome collaborative group, LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
13. Mani A., Radhakrishnan J., Wang H., Mani A., Mani M.A., Nelson-Williams C., Carew K.S., Mane S., Najmabadi H., Wu D., Lifton R.P. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
14. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 2002, 346:1513-1521.
15. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Bénichou O., Scopelliti D., Key L., Renton T., Bartels C., Gong Y., Warman M.L., De Vernejoul M.C., Bollerslev J., Van Hul W. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 2003, 72:763-771.
16. Ai M., Holmen S.L., Van Hul W., Williams B.O., Warman M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell Biol. 2005, 25:4946-4955.
17. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., Hartmann C., Li L., Hwang T.H., Brayton C.F., Lang R.A., Karsenty G., Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 2002, 157:303-314.
18. Holmen S.L., Giambernardi T.A., Zylstra C.R., Buckner-Berghuis B.D., Resau J.H., Hess J.F., Glatt V., Bouxsein M.L., Ai M., Warman M.L., Williams B.O. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res. 2004, 19:2033-2040.
19. Gaur T., Lengner C.J., Hovhannisyan H., Bhat R.A., Bodine P.V., Komm B.S., Javed A., van Wijnen A.J., Stein J.L., Stein G.S., Lian J.B. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 2005, 280:33132-33140.
20. Almeida M., Han L., Bellido T., Manolagas S.C., Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J. Biol. Chem. 2005, 280:41342-41351.
21. Wang Zhongqun, Jiang Yicheng, Liu Naifeng, Ren Liqun, Zhu Yinghong, An Yanli, Chen Dengyu Advanced glycation end-product Nε-carboxymethyl-lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012, 221:387-396.
22. Owen W.F., Hou F.F., Stuart R.O., Kay J., Boyce J., Chertow G.M., Schmidt A.M. β2 -Microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 1998, 53(5):1365-1373.
23. Franke S., Rüster C., Pester J., Hofmann G., Oelzner P., Wolf G. Advanced glycation end products affect growth and function of osteoblasts. Clin. Exp. Rheumato 2011, 29(4):650-660.
24. Zhou Zheng., Immel David, Xi Cai-Xia, Angelika Bierhaus Xu, Feng Lin Mei, Nawroth Peter, Stern David M., Xiong Wen-Cheng Regulation of osteoclast function and bone mass by RAGE. J. Exp. Med. 2006, 203(4):1067-1080.
25. Hay E., Faucheu C., Suc-Royer I., Touitou R., Stiot V., Vayssière B., Baron R., Roman-Roman S., Rawadi G. Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J. Biol. Chem. 2005, 280:13616-13623.
26. Chavakis T., Bierhaus A. Nawroth PP, RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004, 6:1219-1225.
27. Ha E., Laplantine E., Geoffroy V., Frain M., Kohler T., Müller R., Marie P.J. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation. Mol. Cell Biol. 2009, 29(4):953-964.
28. Rybchyn M.S., Slater M., Conigrave A.D., Mason R.S. An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J. Biol. Chem. 2011, 286(27):23771-23779.